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Diuretics have photosensitising properties. However, little is known about how these diuretics affect the risk of skin cancers. In North
Jutland County, Denmark, we investigated whether the use of photosensitising diuretics was associated with an increased risk for
developing basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and malignant melanoma (MM). From the cancer registry, we
identified primary cases of BCC, SCC and MM during the period of 1989–2003. We selected four population controls for each case
from the Danish Civil Registration System, matched on age and gender. Prescriptions for photosensitising diuretics before cancer
diagnosis were ascertained in the county’s Prescription Database. We used conditional logistic regression to compute incidence rate
ratio (IRR), controlling for the chronic medical conditions and for the previous use of oral glucocorticoids. We found an increased risk
of SCC (IRR of 1.79 (95% confidence interval (CI): 1.45–2.21)) and MM (IRR of 1.43 (95% CI: 1.09–1.88)) among users of combined
amiloride and hydrochlorothiazide therapy. An increased risk of MM (IRR of 3.30 (95% CI: 1.34–8.10)) was found among users of
indapamide. We found little associations with risk of BCC. Our findings provide evidence that the use of some photosensitising
diuretics is associated with an increased risk for SCC and MM.
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Most diuretics are photosensitising, including loop diuretics
(bumetanide (Frishman et al, 2002) and furosemide (Moore,
2002)), sodium-saving diuretics (spironolactone (Schwarze et al,
1998) and amiloride (Thestrup-Pedersen, 1987)) and thiazides
(hydrochlorothiazide (Thestrup-Pedersen, 1987), bendroflu-
methiazide (Robinson et al, 1985; Diffey and Langtry, 1989;
Johnston, 2002) and indapamide) with reports on adverse
reactions of sun burns among users of these diuretics. In both
Denmark (Thestrup-Pedersen, 1987) and England (Addo et al,
1987; Diffey and Langtry, 1989), similar reactions have been
reported to occur specifically among those exposed to the
combination of amiloride and hydrochlorothiazide treatment.
There is evidence that a photosensitising reaction followed by
sun exposure may enhance the risk of sunburns and photo damage
that increases risk of skin cancers (Stern, 1998). The mechanism of
drug-induced photosensitivity causing cancer is well-known from
psoralens combined with ultraviolet light-A (PUVA) therapy,
which also increases the risk of squamous cell carcinoma (SCC)
(Stern et al, 1984, 1998; Lindelof et al, 1991; Stern and Laird, 1994)
and malignant melanoma (MM) (Stern, 2001). Although sun burns
as a side effect to these diuretics may arise through the same
mechanism as PUVA treatment, data on the photocarcinogenic
potential of these drugs are limited. To date, only one recent
formal case–control study from the United States investigated
whether the use of photosensitising medications (which included
diuretics) was associated with risk of non-melanoma skin cancers
(NMSCs). On the basis of self-reported drug history, they found an
increased relative risk of basal cell carcinoma (BCC) of 1.5 (95%
confidence interval (CI): 1.0–2.4) and of SCC of 1.8 (95% CI: 1.1–
3.2) if exposed to any of these drugs (Karagas et al, 2007).
However, recall bias (Rothman, 2002) could not be excluded as an
explanation for their findings.
In light of the common use of photosensitising diuretics, we
conducted a large population-based case–control study in
Denmark, examining whether the use of photosensitising diuretics
increases the risk of BCC, SCC and MM.
MATERIALS AND METHODS
We conducted this population-based case–control study in North
Jutland County, with a population of about 500000 inhabitants
(approximately 9% of the Danish population). A unique 10-digit
civil registry number assigned to all Danish residents enabled us to
link national data on cancer incidence, prescription drugs and
hospital discharge diagnoses.
From the Danish Cancer Registry (DCR), we identified all the
patients registered with a first primary diagnosis of BCC, SCC or
MM in North Jutland County from 1989 to 2003. The DCR,
founded in 1943, records primary cases of cancer on a nationwide
basis since 1943 with a high degree of accuracy (Storm et al, 1997).
Data in the DCR include cancer type, site, morphology and date of
diagnosis. Tumours in the DCR are coded according to a modified
Danish version of the seventh revision of the International
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yClassification of Diseases (ICD-7). Since 1978, tumours have been
additionally classified according to the first version of the
International Classification of Diseases for Oncology (ICD-O-1),
which includes a four-digit code for tumour morphology.
We used ICD-7 codes 1910–1919 to identify all BCC and SCC
cases registered in the County of North Jutland during the period
1989–2003. For MM, we used ICD-7 codes 1900–1909. For BCC,
we included only patients with the following ICD-O-1 morphology
codes: 80903, 80913, 80923, 80933 and 81233. For SCC, we included
only patients with the ICD-O-1 codes 80513, 80703, 80713, 80743,
80763, 80943 and 80953. We identified a total of 5964 BCC cases,
1129 SCC cases and 1151 MM cases.
The Civil Registration System contains information about vital
status, date of death and the area of residence of all Danish
residents, and is updated daily (Frank, 2000). Using the Civil
Registration System, we selected approximately four population
controls for each case. Cases and controls were individually
matched by exact age, gender and area of residence based on risk
set sampling (Wacholder et al, 1992) (i.e., the controls had to be
alive, and at risk for a first skin cancer at the time, the
corresponding case was diagnosed (the index date assigned to
controls)). A total of 32412 population controls were selected for
the 8244 BCC, SCC and MM cases.
Data on diuretic prescriptions were obtained from the
Prescription Database in North Jutland County (Nielsen et al,
1997). The database collects data on all prescriptions filled by
ambulatory patients and forwards data on reimbursable medicines
to the local regional Health Service section on a monthly basis.
This Health Service, in turn, refunds 50–75% of costs. The
Prescription Database was established in 1989 (with complete
coverage since 1991) and includes the specific drug prescribed
according to the Anatomical Therapeutical Chemical (ATC)
classification system, the date the prescription was filled, the
packaging size, the number of pills in each package and the
amount of drug in each pill. The ATC codes for the photosensitis-
ing diuretics used in this study are presented in Appendix 1.
In an earlier work, we found that chronic medical conditions
that could be treated with diuretics increased the risk of skin
cancers, that is, chronic pulmonary diseases, connective tissue
diseases, renal diseases, organ transplants, and solid and
haematological cancers (Jensen et al, 2008). To control for the
potentially confounding effects of these chronic medical condi-
tions, we retrieved all hospital diagnoses recorded in the Danish
National Registry of Patients for our study population from 1
January 1977 (the date the Danish National Registry of Patients
was established) to 31 December 2003. Diagnoses are coded
according to the ICD-8 system through 1993 and according to the
ICD-10 system thereafter. The Danish National Registry of Patients
includes 99.4% of all discharge records from Danish hospitals
(Andersen et al, 1999) and, since 1995, encompasses outpatient
and emergency room visits also. For our analyses, we classified the
diagnoses of chronic diseases into six general categories (described
in Appendix 2).
Further, we retrieved prescriptions for oral glucocorticoids from
the Prescription Database (ATC codes in Appendix 1), as the use of
these drugs has been associated with an increased risk of skin
cancers (Karagas et al, 2001; Sorensen et al, 2004) and could be a
potential confounder in our analysis.
Statistical analyses
For each subject, we identified all prescriptions for photosensitis-
ing diuretics before the date of primary skin cancer diagnosis or
index date in the matched control.
We initially examined any prescriptions for diuretics in a
dichotomous model (i.e., any diuretic prescription vs no prescrip-
tions before the index date) for each case group (BCC, SCC and
MM vs controls). We then examined the individual diuretic drugs
by demographic characteristics (age and sex), anatomic site of the
tumour (head and neck vs other sites), prior diagnoses and a
previous prescription for oral glucocorticoids. For the individual
diuretic drugs, we fitted two conditional logistic regression models
for matched pair analysis for each case group (BCC, SCC and MM
vs controls) and prescription of diuretics. The first logistic
regression model treated diuretics as a dichotomous variable.
Amiloride and hydrochlorothiazide was most frequently given as
combination therapy; therefore, we did not control for use of the
other. We attempted to separate the effects of amiloride and
hydrochlorothiazide by classifying prescriptions for ‘amiloride
only’, ‘hydrochlorothiazide only’, ‘both amiloride and hydro-
chlorothiazide’ and ‘none of the drugs’ as reference category. To
examine dose–response relations, we computed the total amount
of prescribed drug before the index date by multiplying the
package size, the number of pills in each package and the amount
of drug in each pill. The total amount of drug dispensed was
included in the model as a continuous (linear) variable with ‘never
prescribed the drug prior to the index date’ as reference category.
When this amount of drug could not be computed (for instance,
due to missing information in the prescription database), the
average amount dispensed for that particular drug was estimated.
Average amounts were used for 0.1% of the prescriptions of
furosemide, 7% of the prescriptions of bumetanide, 24% of the
prescriptions of amiloride, 0.1% of prescriptions of spironolac-
tone, 23% of the prescriptions of hydrochlorothiazide, 10% of the
prescriptions of bendroflumethiazide and 0.2% of the prescrip-
tions of indapamide. In all the models, we included the six chronic
disease categories (as shown in Appendix 2), prior prescription of
a glucocorticoid (yes, no) and prescriptions for the other
photosensitising diuretics (yes, no) as confounding factors.
We also conducted analyses excluding prescriptions issued
within 1 year and 5 years of the skin cancer diagnosis or index date
to evaluate the possibility of heightened detection of skin cancers
due to medical surveillance among those prescribed diuretics (i.e.,
surveillance bias (Rothman, 2002)). These analyses also might
point to possible latency effects (i.e., the period of time from
diuretic exposure to the development of skin cancer). In addition,
we conducted analyses stratified on the anatomic site of the
cancers (i.e., head and neck and other sites) to evaluate the effects
of photosensitising diuretics by the level of sun exposure.
The non-reporting of diagnosed NMSC to the DCR has been
estimated to range from 12 to 40% (Frentz, 1996; Jensen et al,
2007). Therefore, we conducted a sensitivity analysis (Fox et al,
2005a; Greenland, 2005) to explore the magnitude of the effects of
the non-reporting of NMSC cases on our results. We expected that
the non-reporting of NMSC cases could be differential between
users and non-users of photosensitising diuretics; as NMSC is
rarely fatal, in severely diseased patients (such as users of
diuretics), clinicians could potentially deem these cancers trivial
and thereby omit registration. We used the SAS macro written by
Fox et al (2005b), which was adapted to perform conditional
logistic regression.
This study was approved by the Danish Protection Agency
(record no. 2004-41-4693). The statistical software packages R,
version 2.4.1., and SAS, version 9.1 (SAS Institute Inc., Cary, NC,
USA) were used for all statistical analyses.
RESULTS
Subject characteristics
The median age was 69 years among cases with BCC, 77 years
among cases with SCC and 59 years among cases with MM. More
SCC tumours developed on chronically sun-exposed sites (63% on
the head and neck) than BCC or MM tumours (54 and 17% on the
head and neck, respectively). In addition, more cases than controls
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diseases, renal diseases, organ transplants, and solid and
haematological cancers. Also, more cases had a prior prescription
for oral glucocorticoids compared with the controls (data not
shown).
Prescriptions for photosensitising diuretics as risk factors
for developing skin cancer
A total of 1026 (32%) BCC cases had used diuretics compared with
7717 (32%) controls, yielding an incidence rate ratio (IRR) for BCC
of 0.96 (95% CI: 0.90–1.03). Further, there were no clear
associations with any of the individually examined drugs (Table 1).
The risk estimates for BCC of the head and neck were comparable
with those of the other anatomic sites (data not shown).
A total of 493 (44%) SCC cases had used diuretics compared
with 1743 (39%) controls, yielding an IRR for SCC of 1.21 (95% CI:
1.04–1.40). Individually, the use of amiloride, hydrochlorothiazide
and the combination of the two was elevated for SCC cases
compared with controls (Table 2). Among those with a previous
prescription for amiloride, the IRR was 1.80 (95% CI: 1.46–2.20)
and for hydrochlorothiazide, the IRR was 1.58 (95% CI: 1.29–
1.93). Owing to the small number of subjects who were exclusively
prescribed either amiloride or hydrochlorothiazide (0.7 and 0.4%,
respectively), it was difficult to compute their separate effects. On
the basis of small numbers, an elevated IRR was observed for those
prescribed amiloride only (IRR¼2.26; 95% CI: 0.94–5.43), but not
for those prescribed hydrochlorothiazide only (IRR¼0.38; 95% CI:
0.15–0.97). The joint IRR was 1.79 (95% CI: 1.45–2.21) (Table 2).
Among users of all the individual diuretics (except bumetanide
and indapamide), we observed that the estimated risk of SCC
increased linearly with increasing amounts of prescribed drug
(Table 2). Further, we observed an increased risk of SCC among
users of amiloride, hydrochlorothiazide and the two drugs
combined as the period of time from drug exposure to
development of cancer (i.e., latency) increased. The joint IRR
increased to 1.89 (95% CI: 1.52–2.35) with 1-year latency and 1.97
(95% CI: 1.49–2.62) with 5-year latency. This trend was
particularly pronounced among those prescribed amiloride alone
(Table 2). Risk estimates for cases with head and neck SCC were
similar to those with SCC tumours at other anatomic sites (data
not shown).
A total of 312 (27%) MM cases had used diuretics compared
with 1124 (24%) controls, yielding an IRR for MM of 1.19 (95% CI:
1.01–1.41). For MM, we also observed an increased risk among
those individually prescribed amiloride and hydrochlorothiazide
(IRR¼1.39; 95% CI: 1.06–1.81 and IRR¼1.32; 95% CI: 1.03–1.70,
respectively). Again, there were few cases who were prescribed
exclusively one of these drugs; but as with SCC, the IRR was
increased for prescription of amiloride only (IRR¼1.21; 95% CI:
0.39–3.74), but not for hydrochlorothiazide only (IRR¼0.87; 95%
CI: 0.45–1.68). For prescription of combined therapy, the IRR was
1.43 (95% CI: 1.09–1.88) overall and somewhat higher for head
and neck tumours (IRR of 2.15; 95% CI: 1.19–3.88 (data not
Table 1 Use of photosensitising diuretics and risk of basal cell carcinoma
Basal cell carcinoma
Any prescription before diagnosis date Prescriptions 41 year
before diagnosis
Prescriptions 45
year before diagnosis
Number of cases
N¼5964
Number of controls
N¼23856
IRR adjusted
(95% CI)
IRR adjusted
(95% CI)
IRR adjusted
(95% CI)
Loop diuretics
Furosemide 830 (14%) 3422 (14%) 0.91 (0.83–0.99) 0.90 (0.82–0.99) 0.95 (0.83–1.09)
Linear increase per 10000mg 1.00 (0.99–1.01)
Bumetanide 46 (0.8%) 211 (0.9%) 0.86 (0.62–1.19) 0.76 (0.53–1.09) 0.98 (0.59–1.63)
Linear increase per 10000mg 0.88 (0.16–4.66)
Potassium-saving diuretics
Amiloride 482 (8%) 1849 (7.8%) 1.04 (0.93–1.16) 1.03 (0.92–1.15) 1.11 (0.96–1.28)
Linear increase per 10000mg 1.13 (0.98–1.31)
Spironolactone 145 (2.4%) 539 (2.3%) 1.06 (0.87–1.28) 1.10 (0.89–1.37) 1.20 (0.86–1.68)
Linear increase per 10000mg 1.04 (1.01–1.07)
Thiazide diuretics
Bendroflumethiazide 1069 (18%) 4291 (18%) 0.98 (0.90–1.06) 1.00 (0.91–1.08) 0.98 (0.87–1.10)
Linear increase per 10000mg 0.95 (0.80–1.13)
Indapamide 24 (0.4%) 94 (0.4%) 0.99 (0.63–1.56) 0.94 (0.57–1.55) 0.90 (0.43–1.87)
Linear increase per 10000mg 0.88 (0.13–5.78)
Hydrochlorothiazide 542 (9%) 2059 (8.6%) 1.05 (0.95–1.16) 1.05 (0.94–1.17) 1.10 (0.95–1.26)
Linear increase per 10000mg 1.02 (1.00–1.03)
Combined therapy
Amiloride only 24 (0.4%) 86 (0.4%) 1.18 (0.75–1.87) 0.92 (0.54–1.55) 0.93 (0.78–1.11)
Linear increase per 10000mg
a
Hydrochlorothiazide only 84 (1.4%) 296 (1.2%) 1.14 (0.89–1.46) 1.17 (0.88–1.55) 0.97 (0.52–1.76)
Linear increase per 10000mg
a
Amiloride and hydrochlorothiazide 458 (8%) 1763 (7%) 1.04 (0.93–1.16)
a
1.03 (0.92–1.16) 1.10 (0.95–1.27)
Linear increase per 10000mg
CI¼confidence interval; IRR¼incidence rate ratio. The reference group was different for each diuretic, as the reference group was ‘never users the particular diuretic under
study’. Conditional logistic regression was used to estimate IRRs and 95% CI, adjustments were made for a prior hospitalisation for selected chronic diseases and use of
glucocorticoids.
aNot possible because of low proportions of cases or because of combined therapy.
Photosensitising diuretics and risk of skin cancer
AØ Jensen et al
1524
British Journal of Cancer (2008) 99(9), 1522–1528 & 2008 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yshown)) compared with other anatomic sites. For MM, we also
found an increased risk associated with use of indapamide
(IRR¼3.30; 95% CI: 1.34–8.10) (Table 3). Further, we observed
a trend of an increasing risk of MM among users of indapamide, as
the period of time from drug exposure to development of cancer
(i.e., latency) increased. The IRR increased to 3.85 (95% CI: 1.47–
10) with a 1 or more year latency and 6.06 (95% CI: 1.78–21) with
a 5 or more year latency (Table 3).
Sensitivity analyses simulating the non-reporting of NMSC
cases
The sensitivity analyses showed that if we adjusted for a
differential underascertainment of NMSC cases from 5 to 45%
(trapezoidal distribution) among those prescribed diuretics, the
resulting risk estimates for NMSC among those who were
prescribed diuretics increased by a factor varying from 1.1 to
1.5, depending on the diuretic type (data not shown).
DISCUSSION
We found an increased risk of SCC and MM among the users of
diuretics. We found an individual association between the use
of combined amiloride–hydrochlorothiazide therapy and the risk
of SCC, and an association, albeit weaker, between this therapy and
MM. We also found evidence of a possible relation between
indapamide use and risk of MM. We observed a trend of increasing
risk with amount of drug and length of time between prescription
and diagnosis (i.e., latency).
The mechanism of drug-induced photosensitivity causing
cancer is well-known from observations of patients treated with
PUVA therapy. These patients have increased risks of SCC and
MM (Stern et al, 1984, 1998; Lindelof et al, 1991; Stern and Laird,
1994; Stern, 2001). It is of further interest to note that findings
among those PUVA-treated patients show a clear dose–response
relationship and latency effect on SCC risk (Stern et al, 1998).
Similarly, we found an increased risk of SCC with increasing
amount of prescribed amiloride and hydrochlorothiazide. This was
particularly true for amiloride, which has a maximal absorbance in
the UV-A spectrum (Moore, 2002). In contrast, we detected an
effect of users of indapamide on MM risk, and this drug has a
maximal absorbance in the UV-B spectrum (Davis et al, 1979).
This may indicate a difference in wavelengths responsible for the
distinct histologic types of skin cancer. Furthermore, only UV-B
has been found to induce MM in transgenic mice (Larue et al,
1992).
In contrast, we did not find the same convincing association
with use of photosensitising diuretics and risk of BCC. This is
consistent with the studies relating sun exposure and BCC risk that
indicate that the time between the carcinogenic UV exposure and
the development of BCC is longer than that for SCC and that
younger persons may be more susceptible to these effects than
older persons (Gallagher et al, 1995).
Table 2 Use of photosensitising diuretics and risk of squamous cell carcinoma
Squamous cell carcinoma
Any prescription before diagnosis date Prescriptions 41 year
before diagnosis
Prescriptions 45 year
before diagnosis
Number of cases
N¼1129
Number of controls
N¼4516
IRR adjusted
(95% CI)
IRR adjusted
(95% CI)
IRR adjusted
(95% CI)
Loop diuretics
Furosemide 235 (21%) 878 (19%) 0.94 (0.78–1.12) 0.91 (0.75–1.11) 0.92 (0.69–1.23)
Linear increase per 10000mg 1.01 (0.99–1.02)
Bumetanide 9 (0.8%) 48 (1.1%) 0.71 (0.35–1.47) 0.63 (0.28–1.43) 0.89 (0.29–2.72)
Linear increase per 10000mg 4.78 (0.53–43)
Potassium-saving diuretics
Amiloride 162 (14%) 390 (9%) 1.80 (1.46–2.20) 1.90 (1.54–2.35) 1.98 (1.50–2.61)
Linear increase per 10000mg 1.31 (1.00–1.71)
Spironolactone 38 (3.4%) 121 (2.7%) 1.11 (0.75–1.65) 1.00 (0.64–1.57) 0.90 (0.44–1.84)
Linear increase per 10000mg 1.00 (0.92–1.09)
Thiazide diuretics
Bendroflumethiazide 241 (21%) 913 (20%) 1.03 (0.86–1.22) 0.91 (0.76–1.10) 1.03 (0.79–1.34)
Linear increase per 10000mg 0.98 (0.71–1.34)
Indapamide 10 (0.9%) 29 (0.6%) 1.20 (0.57–2.54) 1.10 (0.49–2.46) 1.02 (0.32–3.23)
a
Hydrochlorothiazide 159 (14%) 427 (10%) 1.58 (1.29–1.93) 1.67 (1.36–2.07) 1.92 (1.46–2.54)
Linear increase per 10000mg 1.03 (1.01–1.06)
Combined therapy
Amiloride only 8 (0.7%) 18 (0.4%) 2.26 (0.94–5.43) 2.51 (1.03–6.13) 3.42 (0.75–15.6)
Linear increase per 10000mg
a
Hydrochlorothiazide only 5 (0.4%) 55 (1.2%) 0.38 (0.15–0.97) 0.29 (0.09–0.94) 1.33 (0.25–6.93)
Linear increase per 10000mg
a
Amiloride and hydrochlorothiazide 154 (14%) 372 (8%) 1.79 (1.45–2.21) 1.89 (1.52–2.35) 1.97 (1.49–2.62)
Linear increase per 10000mg
a
CI¼confidence interval; IRR¼incidence rate ratio. The reference group was different for each diuretic, as the reference group was ‘the never users the particular diuretic under
study’. Conditional logistic regression was used to IRRs and 95% CI, adjustments were made for a prior hospitalisation for selected chronic diseases and use of glucocorticoids.
The linear increase per 10000mg prescribed drug translates to the average percentage increase per 10000mg of prescribed drug.
aNot possible because of low proportions of
cases or because of combined therapy.
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the uniformly organised Danish health-care system allows a true
population-based design. Data on photosensitising diuretics were
collected prospectively and independent of the cancer data,
limiting the potential for recall bias found in interview-based
studies on the same topic (Karagas et al, 2007). Moreover, our
approach included assessment of the potential effects of a
surveillance bias by excluding the use within 1 year of the cancer
diagnoses; we found this bias to be slight. Finally, we considered
the possibility that other factors may be confounding the
association observed with photosensitising diuretics, and we were
able to control prescriptions of glucocorticoids and a prior history
for selected chronic diseases.
Among the limitations of our study was the reliance on
prescription data and, specifically, the use of filling of prescrip-
tions as a surrogate for actual using of the drugs (non-adherence).
This could lead to misclassification of some non-users as users,
potentially biasing our results towards unity. Still, the users had
redeemed and paid for the drug; therefore, this bias is likely to be
small. Another source of bias is that the records of NMSC may be
incomplete in the DCR (Frentz, 1996; Frentz and Olsen, 1999). As
NMSC is rarely fatal, in severely diseased patients, such as diuretic
users, clinicians potentially could deem the NMSC trivial and
therefore omit registration (differential registration). As shown by
the sensitivity analyses, this potential underascertainment of
NMSC cases using diuretics in our case–control study could have
led to a substantial underestimation of the overall effect of
diuretics on the risk of SCC and BCC.
As a register linkage study, we did not have information
about skin phenotypes (i.e., skin sensitivity to sunlight and
sun exposure). It is conceivable that patients with a sun-sensitive
phenotype take more precaution when warned about the sun-
sensitising effects of diuretics. If so, this could potentially
underestimate the risk association, we observed. Another
limitation is that some of the drug effects, that is ‘amiloride
only’, ‘hydrochlorothiazide only’ and ‘indapamide’, as well as
the drug-amount and latency trends were based on low
proportions of cases. Therefore, these risk estimates had
very limited statistical precision and should be interpreted with
caution.
In conclusion, our large case–control study indicates a potential
relation between commonly prescribed diuretics and risks of SCC
and MM in the Danish population.
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Table 3 Use of photosensitising diuretics and risk of malignant melanoma
Malignant melanoma
Any prescription before diagnosis date Prescriptions 41 year
before diagnosis
Prescriptions 45 year
before diagnosis
Number of
cases N¼1010
Number of controls
N¼4040
IRR adjusted
(95% CI)
IRR adjusted
(95% CI)
IRR adjusted
(95% CI)
Loop diuretics
Furosemide 116 (10%) 487 (11%) 0.91 (0.72–1.16) 0.90 (0.69–1.16) 0.90 (0.63–1.29)
Linear increase per 10000mg 1.01 (0.99–1.03)
Bumetanide 6 (0.5%) 29 (0.6%) 0.75 (0.29–1.90) 0.79 (0.28–2.23) 0.69 (0.18–2.61)
Linear increase per 10000mg 0.20 (0.00–202)
Potassium-saving diuretics
Amiloride 90 (8%) 272 (6%) 1.39 (1.06–1.81) 1.33 (1.00–1.77) 1.29 (0.89–1.86)
Linear increase per 10000mg 0.76 (0.50–1.17)
Spironolactone 14 (1.2%) 67 (1.5%) 0.84 (0.46–1.54) 0.91 (0.46–1.79) 0.71 (0.26–1.93)
Linear increase per 10000mg 1.01 (0.94–1.09)
Thiazide diuretics
Bendroflumethiazide 168 (15%) 616 (13%) 1.08 (0.88–1.32) 1.06 (0.86–1.32) 1.01 (0.74–1.37)
Linear increase per 10000mg 1.11 (0.70–1.75)
Indapamide 10 (0.9%) 12 (0.3%) 3.30 (1.34–8.10) 3.85 (1.47–10.1) 6.06 (1.78–20.7)
Linear increase per 10000mg 5.81 (0.07–464)
Hydrochlorothiazide 98 (9%) 303 (7%) 1.32 (1.03–1.70) 1.30 (0.99–1.71) 1.24 (0.86–1.78)
Linear increase per 10000mg 0.99 (0.95–1.03)
Combined therapy
Amiloride only 5 (0.4%) 15 (0.3%) 1.21 (0.39–3.74) 1.10 (0.31–3.95) 2.56 (0.44- 14.9)
Linear increase per 10000mg
a
Hydrochlorothiazide only 13 (1.1%) 46 (1.0%) 0.87 (0.45–1.68) 0.91 (0.43–1.92) 0.89 (0.26–3.03)
Linear increase per 10000mg
a
Amiloride and hydrochlorothiazide 85 (7%) 257 (6%) 1.43 (1.09–1.88) 1.37 (1.02–1.83) 1.28 (0.87–1.86)
Linear increase per 10000mg
a
CI¼confidence interval; IRR¼incidence rate ratio. The reference group was different for each diuretic, as the reference group was ‘the never users the particular diuretic under
study’. Conditional logistic regression was used to estimate IRRs and 95% CI, adjustments were made for a prior hospitalisation for selected chronic diseases and use of
glucocorticoids.
aNot possible because of low proportions of cases or because of combined therapy.
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Appendix 1
The anatomical therapeutical chemical (ATC) codes for the diuretics and the glucocorticoids
Photosensitising diuretics/glucocorticoids ATC codes
Furosemide C03CA01, C03EB01
Bumetanide C03CA02, C03EB02
Amiloride C03EA01
Spironolactone C03DA01
Hydrochlorothiazide C03EA01, C07BB02, C09BA01, C09BA02, C09BA03,
C09BA05, C09DA06, C09DA04, C09DA01, C09DA07, C09DA02 and C09DA03
Bendroflumethiazide C03AA01
Indapamide C03BA11
Budenoside A07EA06
Hydrocortisone A07EA02, H02AB09
Prednisolone A07EA01, H02AB06
Prednisone H02AB07
Betamethasone H02AB01
Methylprednisolone H02AB04
Triamcinolone H02AB08
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Translation of disease categories of chronic diseases into discharge diagnoses in ICD-8 and ICD-10
Disease category Diseases ICD-8 ICD-10
Chronic pulmonary disease Emphysema and chronic
obstructive lung disease
490–493; 515–518 J40–J47; J60–J67; J68.4; J70.1; J70.3;
J84.1; J92.0; J96.1; J98.2; J98.3
Connective tissue disease Diffuse connective tissue disease,
rheumatoid arthritis and other
inflammatory polyarthropathies and
polymyalgia rheumatica
712; 716; 734; 446; 135.99 M05; M06; M08; M09; M30–M36;
D86
Moderate-to-severe renal disease Glomerulonephritis, nephropathies
and end-stage renal disease
403; 404; 580–583; 584; 590.09;
593.19; 753.10–753.19; 792
I12; I13; N00–N05; N07; N11;
N14; N17–N19; Q61
Organ transplants Heart, kidney, liver and bone
marrow transplantation
Y9509 Z94
Any solid cancer except skin cancer
and metastasis
Any solid cancer except skin cancer
and metastasis
140–199, except 172 and 173 C00–C80, except C43–C44
Leukaemia and Lymphoma Non-Hodgkin and Hodgkin
lymphoma and multiple myeloma
200–207; 275.59 C81–C85; C88; C90–C96
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